What are the specifications of gaffetuzumab?

Glofitumab is an innovative immunotherapy using a bispecific antibody design and is widely used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and large B-cell lymphoma (LBCL) caused by follicular lymphoma. Its main ingredients and specifications are as follows:

The common specification of Gerfitumab is10mg/10ml injection. This specification is very common in clinical treatment and is suitable for the treatment needs of most patients. Each vial of 10 mg/10 ml solution provides a concentration that allows easy adjustment of dosage during treatment. Typically, gaffetuzumab is administered as a subcutaneous injection, and patients receive treatment in a hospital or specialized medical facility. Due to its special targeting mechanism, gaffetuzumab can effectively mobilize the immune system to attack tumor cells, showing high effectiveness in the treatment of relapsed lymphoma.

In actual use, the dose adjustment of greffitumab is usually managed on an individual basis based on factors such as the patient's weight, condition, and immune response. The drug's dose escalation schedule usually starts with an initial low dose and gradually increases to a therapeutic dose to improve efficacy and reduce the occurrence of side effects. For patients requiring long-term treatment, regular monitoring of the effects and side effects of medications is critical.

The specifications and dosage design of gaffetuzumab help to increase the flexibility of treatment, allowing clinicians to adjust the treatment plan according to the specific conditions of the patient to obtain the best treatment effect. Not only is the drug suitable for patients with relapsed or refractory lymphoma, it also exhibits a relatively low risk of side effects, making it an ideal treatment option. For those patients who have no other effective treatment options, gaffetuzumab represents a breakthrough in the treatment of lymphoma by providing a valuable therapeutic opportunity.

Reference materials:https://www.drugs.com/glofitamab.html